Mounjaro in Nottingham: what the clinical evidence actually shows

What the SURMOUNT trial data tells people in Nottingham considering Mounjaro

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and no diabetes to tirzepatide or placebo over 72 weeks. At the 15mg dose, participants lost an average of around 20–21% of their body weight. To put that in everyday terms: someone starting at 100kg could expect, on average, to lose around 20kg over the course of the trial. Those are not hand-picked results from the best performers, they are average figures across the treatment group.

A later head-to-head comparison, the SURMOUNT-5 trial, placed tirzepatide directly against semaglutide 2.4mg (the active ingredient in Wegovy) over 72 weeks. Tirzepatide produced greater average weight loss. NICE reviewed this evidence in its appraisal of tirzepatide and, in Technology Appraisal TA1026, recommended the medicine for use within the NHS under specific eligibility criteria. Understanding that guidance matters if you are exploring what treatment might look like for you.

The dual mechanism is part of why the results stand out. Most GLP-1 medicines activate a single receptor involved in appetite and blood-sugar control. Tirzepatide activates both GIP and GLP-1 receptors, slowing gastric emptying and increasing feelings of fullness through two complementary pathways. It is the only medicine with this profile that is licensed for weight management in the UK.

Who the evidence supports: eligibility as it applies in practice

For NHS access, NICE TA1026 sets the bar at a BMI of 35 or above plus at least one qualifying condition from a list that includes high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. NHS rollout is phased: from around June 2026, the threshold opened to a BMI of 35–39.9 with four or more of those conditions. For South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, thresholds are 2.5 kg/m² lower throughout.

For private prescribing, the licensed eligibility is broader: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, may be assessed. BMI is a starting point, not a guarantee. A prescriber looks at the full clinical picture (current medicines, medical history, any contraindications) before deciding whether Mounjaro is appropriate for you. If you are curious about what the process involves at a private pharmacy, our page on getting Mounjaro explains each step.

One thing worth being honest about: many people in Nottingham researching this online feel a mixture of hope and scepticism. The results in trials are real, but they were achieved alongside reduced-calorie eating and increased activity. The medicine changes appetite significantly; sustaining that alongside lifestyle habits is where the clinical relationship matters.

Side effects and what the evidence says about managing them

The most commonly reported side effects in the SURMOUNT trials were gastrointestinal: nausea, diarrhoea, constipation, vomiting and indigestion. These were most pronounced after starting treatment or after a dose increase, and they generally eased within one to two weeks as the body adjusted. The slow titration schedule (starting at 2.5mg before moving up) exists specifically to give your system time to settle. The NHS tirzepatide medicines page sets out the full side-effect profile and what to watch for.

The MHRA issued a Drug Safety Update in January 2026 flagging acute pancreatitis as an infrequent but serious risk across GLP-1 medicines. If you develop severe stomach pain that spreads to the back, with or without vomiting, seek urgent medical help. This applies whether you are prescribed through an NHS service or a regulated private provider. Reporting any unexpected effects via the Yellow Card scheme at yellowcard.mhra.gov.uk contributes to post-market safety data and is something any prescriber will encourage.

Mounjaro is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive. It is not licensed for anyone under 18. Women taking oral contraceptives should discuss contraception with their prescriber when starting tirzepatide, as pill absorption may be reduced during the first weeks of treatment and after each dose step up; our page on whether Mounjaro causes spotting covers how hormonal changes during treatment can affect the menstrual cycle.

Private access in Nottingham: what a regulated online pharmacy actually means

You do not need to attend a clinic in Nottingham to access Mounjaro privately, and if you are based in the area our page on Mounjaro in Birmingham is also worth reading if you are comparing nearby private providers. A GPhC-registered online pharmacy operates under the same regulatory framework as any high-street pharmacy in Nottinghamshire. The distinction that matters is whether the pharmacy appears on the GPhC register and whether a qualified Independent Prescriber reviews your consultation, not a set of automated rules.

For context on what private treatment costs across providers, our Mounjaro price comparison page sets out what market prices look like and what legitimate pricing typically includes. Since Eli Lilly raised UK list prices in September 2025, the private market has adjusted; any quoted price should include the clinical assessment and prescription, not just the pen.

At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber. If clinically approved and your order is placed before noon on a working day, treatment is dispatched the same day and delivered free the next working day by DPD, in plain packaging. There are no subscriptions and no auto-renewals. Our about us page explains how the service is structured, and our clinical team is named and verifiable. If weight loss has stalled or reversed during treatment, our pages on why you might be putting on weight on Mounjaro and on putting weight on with Mounjaro explore the reasons this can happen and what steps are worth considering. If you are ready to find out whether you are suitable, speak to our prescribers through a free consultation.